Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 in Huntington's Disease
NCT05655520Phase 3Terminated
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
Phase 3, open-label trial of dalzanemdor in Huntington's disease (HD) (3 cohorts), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 24 months, Treatment-Emergent Adverse Events by Severity at 24 months and 12 more. Started Dec 2022; status: terminated.
02
Drugs
dalzanemdor
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05655520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655520.